Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gilbert Kepecs

Rheumatology Hackensack, NJ Medical Doctor

NPI 1093710014 CMS profile 275664

385 Prospect Ave, Hackensack, NJ 07601

Open in the dashboard

General payments

$7,890

507 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gilbert Kepecs of Hackensack, NJ is reported in the CMS Open Payments database as having received $7,890 across 507 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,272 70
2024 General $1,196 65
2023 General $1,330 87
2022 General $989 71
2021 General $1,003 70
2020 General $944 62
2019 General $1,158 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gilbert Kepecs
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Gilbert Kepecs were reported at $1,272. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Gilbert Kepecs Rheumatology median Middle half National median
2019 $1,158 $744 $153–$2,687 $163
2020 $944 $462 $98–$2,027 $114
2021 $1,003 $531 $101–$2,153 $132
2022 $989 $627 $125–$2,303 $149
2023 $1,330 $741 $145–$2,524 $160
2024 $1,196 $830 $166–$2,660 $164
2025 $1,272 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,892 119 payments
  2. AbbVie, Inc. $1,225 86 payments
  3. Janssen Biotech, Inc. $963 45 payments
  4. UCB, Inc. $894 59 payments
  5. Novartis Pharmaceuticals Corporation $505 27 payments
  6. Pfizer Inc. $401 38 payments
  7. Organon LLC $280 19 payments
  8. Lilly USA, LLC $252 18 payments
  9. GlaxoSmithKline, LLC. $248 18 payments
  10. E.R. Squibb & Sons, L.L.C. $211 16 payments
  11. Other $1,018 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,455 502 payments
  2. Education $435 5 payments
Products named General payments · program years 2019–2025
  1. EVENITY $862 54 payments
  2. TREMFYA $726 26 payments
  3. RINVOQ $716 49 payments
  4. Prolia $669 49 payments
  5. Cimzia $642 45 payments
  6. SIMPONI ARIA $441 24 payments
  7. TAVNEOS $422 22 payments
  8. XELJANZ $388 37 payments
  9. COSENTYX $298 13 payments
  10. Bimzelx $252 14 payments
  11. Other $3,683 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

4,378

Median for Rheumatology: 1,511

Drug cost

$2,467,183

Median for Rheumatology: $1,139,948

Branded share of claims

21.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 64 $477,959
Humira(Cf) Pen Adalimumab Brand 51 $428,471
Enbrel Mini Etanercept Brand 52 $409,698
Xeljanz Xr Tofacitinib Citrate Brand 43 $246,323
Enbrel Etanercept Brand 30 $216,643
Enbrel Sureclick Etanercept Brand 19 $150,795
Humira(Cf) Adalimumab Brand 11 $146,754
Cosentyx Sensoready (2 Pens) Secukinumab Brand 15 $98,921
Otezla Apremilast Brand 14 $66,490
Actemra Tocilizumab Brand 11 $51,817

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$1,285,851

Of which drugs: $1,055,612

Medicare patients

517

Average age 75

Services billed

138,531

386 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 47%
Ischemic heart disease 38%
Diabetes 32%
Depression 22%
Heart failure 18%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 98 10,140 $208,346
Vaccine for influenza for injection into muscle 90662 Office 18 19 $1,535
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 14 5,887 $1,239
Injection, methylprednisolone acetate, 1 mg J1010 Office 87 3,573 $369
Injection, zoledronic acid, 1 mg J3489 Office 15 75 $360
Injection, methylprednisolone acetate, 20 mg J1020 Office 26 30 $142
Injection, methylprednisolone acetate, 40 mg J1030 Office 13 17 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$219 — —
Cimzia
$111 — —
RINVOQ
$102 64 —
SIMPONI ARIA
$90 — —
TAVNEOS
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

507 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record